港股異動 | 基石藥業(2616.HK)高開7.66% 將攜手輝瑞共同開發肺癌新藥勞拉替尼
格隆匯6月16日丨基石藥業(2616.HK)高開7.66%,現報15.18港元,最新市值179億港元。基石藥業昨日宣佈,將與輝瑞在大中華地區針對ROS1陽性晚期非小細胞肺癌(NSCLC)開展合作研究,共同開發勞拉替尼(lorlatinib)。此項在中國即將開展的ROS1陽性肺癌的臨牀研究是勞拉替尼在該靶點的全球首次關鍵性研究。這是繼去年基石藥業與輝瑞達成戰略合作後,雙方合作的進一步深化。基石藥業董事長兼首席執行官江寧軍博士表示:“此次進一步合作充分體現了輝瑞對基石藥業強大的臨牀開發能力的認可,同時,基石藥業的研發管線得到了進一步擴充。我們期待和輝瑞強強聯手,高質、高效地將更多的創新腫瘤治療產品帶給廣大患者。”

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.